Cancer Cell

, том 19 , издание 1 , страницы 101-113

An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells

Nicholas C. Wilson ¹

Becky Yang ¹

Annie Yang ¹

Stefanie Loeser ²

Scot Marsters ¹

David M. Lawrence ¹

Yun Li ¹

Robert Pitti ¹

KLARA TOTPAL ³

Sharon Yee ³

Sarajane Ross ³

Jean-Michel Vernes ⁴

Yanmei Lu ⁴

Cam Adams ⁵

Rienk Offringa ²

Bob Kelley ⁵

Sarah G. Hymowitz ⁶

Dylan Daniel ¹

Gloria Meng ⁴

Avi Ashkenazi ¹

Скрыть аффилиации авторов Показать аффилиации авторов: 6 аффилиаций

Department of Molecular Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA. |

Department of Discovery Immunology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA |

Department of Cancer Signaling and Translational Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA |

⁴

Department of Assay & Automation Technology, Genentech, Inc. 1 DNA Way, South San Francisco, CA 94080, USA |

⁵

Department of Antibody Engineering, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA. |

⁶

Department of Structural Biology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA |

Тип публикации: Journal Article

Дата публикации: 2011-01-20

Elsevier

Cancer Cell

scimago Q1

wos Q1

БС1

SJR: 19.027

CiteScore: 57.7

Impact factor: 44.5

ISSN: 15356108, 18783686

DOI: 10.1016/j.ccr.2010.11.012

Скопировать DOI

PubMed ID: 21251615

Cancer Research

Oncology

Cell Biology

Краткое описание

Antibodies to cell-surface antigens trigger activatory Fcγ receptor (FcγR)-mediated retrograde signals in leukocytes to control immune effector functions. Here, we uncover an FcγR mechanism that drives antibody-dependent forward signaling in target cells. Agonistic antibodies to death receptor 5 (DR5) induce cancer-cell apoptosis and are in clinical trials; however, their mechanism of action in vivo is not fully defined. Interaction of the DR5-agonistic antibody drozitumab with leukocyte FcγRs promoted DR5-mediated tumor-cell apoptosis. Whereas the anti-CD20 antibody rituximab required activatory FcγRs for tumoricidal function, drozitumab was effective in the context of either activatory or inhibitory FcγRs. A CD40-agonistic antibody required similar FcγR interactions to stimulate nuclear factor-κB activity in B cells. Thus, FcγRs can drive antibody-mediated receptor signaling in target cells.

Найдено

1 цитирование

Яголович Анна

🥼 🤝

к.б.н., ассистент

31 публикация, 279 цитирований, 4 рецензии

Индекс Хирша: 10

Московский государственный университет имени М.В. Ломоносова

Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН

Области научных интересов

Апоптоз

1 цитирование

Нагата Сатоши

50 публикаций, 1 746 цитирований, 2 рецензии

Индекс Хирша: 26

Национальный институт биомедицинских инноваций, здравоохранения и питания

Топ-30

Журналы

	2 4 6 8 10
Cancer Cell	Cancer Cell, 10, 4.33% Cancer Cell 10 публикаций, 4.33%
Nature Reviews Drug Discovery	Nature Reviews Drug Discovery, 7, 3.03% Nature Reviews Drug Discovery 7 публикаций, 3.03%
mAbs	mAbs, 7, 3.03% mAbs 7 публикаций, 3.03%
Molecular Cancer Therapeutics	Molecular Cancer Therapeutics, 7, 3.03% Molecular Cancer Therapeutics 7 публикаций, 3.03%
Cancers	Cancers, 6, 2.6% Cancers 6 публикаций, 2.6%
Cell Death and Differentiation	Cell Death and Differentiation, 6, 2.6% Cell Death and Differentiation 6 публикаций, 2.6%
Cell Death and Disease	Cell Death and Disease, 6, 2.6% Cell Death and Disease 6 публикаций, 2.6%
Journal of Immunology	Journal of Immunology, 5, 2.16% Journal of Immunology 5 публикаций, 2.16%
Clinical Cancer Research	Clinical Cancer Research, 5, 2.16% Clinical Cancer Research 5 публикаций, 2.16%
Journal of Biological Chemistry	Journal of Biological Chemistry, 4, 1.73% Journal of Biological Chemistry 4 публикации, 1.73%
OncoImmunology	OncoImmunology, 4, 1.73% OncoImmunology 4 публикации, 1.73%
Journal of Experimental Medicine	Journal of Experimental Medicine, 4, 1.73% Journal of Experimental Medicine 4 публикации, 1.73%
Journal of Clinical Investigation	Journal of Clinical Investigation, 3, 1.3% Journal of Clinical Investigation 3 публикации, 1.3%
Science	Science, 3, 1.3% Science 3 публикации, 1.3%
Cancer immunology research	Cancer immunology research, 3, 1.3% Cancer immunology research 3 публикации, 1.3%
Proceedings of the National Academy of Sciences of the United States of America	Proceedings of the National Academy of Sciences of the United States of America, 3, 1.3% Proceedings of the National Academy of Sciences of the United States of America 3 публикации, 1.3%
Expert Opinion on Therapeutic Targets	Expert Opinion on Therapeutic Targets, 2, 0.87% Expert Opinion on Therapeutic Targets 2 публикации, 0.87%
Nature Cancer	Nature Cancer, 2, 0.87% Nature Cancer 2 публикации, 0.87%
Oncotarget	Oncotarget, 2, 0.87% Oncotarget 2 публикации, 0.87%
Antibodies	Antibodies, 2, 0.87% Antibodies 2 публикации, 0.87%
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 2, 0.87% International Journal of Molecular Sciences 2 публикации, 0.87%
Frontiers in Immunology	Frontiers in Immunology, 2, 0.87% Frontiers in Immunology 2 публикации, 0.87%
Cellular and Molecular Immunology	Cellular and Molecular Immunology, 2, 0.87% Cellular and Molecular Immunology 2 публикации, 0.87%
Current Oncology Reports	Current Oncology Reports, 2, 0.87% Current Oncology Reports 2 публикации, 0.87%
Cancer Immunology, Immunotherapy	Cancer Immunology, Immunotherapy, 2, 0.87% Cancer Immunology, Immunotherapy 2 публикации, 0.87%
Scientific Reports	Scientific Reports, 2, 0.87% Scientific Reports 2 публикации, 0.87%
Nature Immunology	Nature Immunology, 2, 0.87% Nature Immunology 2 публикации, 0.87%
Nature Reviews Clinical Oncology	Nature Reviews Clinical Oncology, 2, 0.87% Nature Reviews Clinical Oncology 2 публикации, 0.87%
Nature Communications	Nature Communications, 2, 0.87% Nature Communications 2 публикации, 0.87%
	2 4 6 8 10

Издатели

	10 20 30 40 50 60
Springer Nature	Springer Nature, 57, 24.68% Springer Nature 57 публикаций, 24.68%
Elsevier	Elsevier, 47, 20.35% Elsevier 47 публикаций, 20.35%
Taylor & Francis	Taylor & Francis, 20, 8.66% Taylor & Francis 20 публикаций, 8.66%
American Association for Cancer Research (AACR)	American Association for Cancer Research (AACR), 16, 6.93% American Association for Cancer Research (AACR) 16 публикаций, 6.93%
Wiley	Wiley, 13, 5.63% Wiley 13 публикаций, 5.63%
MDPI	MDPI, 12, 5.19% MDPI 12 публикаций, 5.19%
The American Association of Immunologists	The American Association of Immunologists, 5, 2.16% The American Association of Immunologists 5 публикаций, 2.16%
Frontiers Media S.A.	Frontiers Media S.A., 5, 2.16% Frontiers Media S.A. 5 публикаций, 2.16%
American Association for the Advancement of Science (AAAS)	American Association for the Advancement of Science (AAAS), 5, 2.16% American Association for the Advancement of Science (AAAS) 5 публикаций, 2.16%
American Society for Clinical Investigation	American Society for Clinical Investigation, 4, 1.73% American Society for Clinical Investigation 4 публикации, 1.73%
American Society for Biochemistry and Molecular Biology	American Society for Biochemistry and Molecular Biology, 4, 1.73% American Society for Biochemistry and Molecular Biology 4 публикации, 1.73%
Rockefeller University Press	Rockefeller University Press, 4, 1.73% Rockefeller University Press 4 публикации, 1.73%
BMJ	BMJ, 3, 1.3% BMJ 3 публикации, 1.3%
Proceedings of the National Academy of Sciences (PNAS)	Proceedings of the National Academy of Sciences (PNAS), 3, 1.3% Proceedings of the National Academy of Sciences (PNAS) 3 публикации, 1.3%
American Society of Hematology	American Society of Hematology, 3, 1.3% American Society of Hematology 3 публикации, 1.3%
American Chemical Society (ACS)	American Chemical Society (ACS), 3, 1.3% American Chemical Society (ACS) 3 публикации, 1.3%
Impact Journals	Impact Journals, 2, 0.87% Impact Journals 2 публикации, 0.87%
Ovid Technologies (Wolters Kluwer Health)	Ovid Technologies (Wolters Kluwer Health), 2, 0.87% Ovid Technologies (Wolters Kluwer Health) 2 публикации, 0.87%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii	Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii, 2, 0.87% Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii 2 публикации, 0.87%
Oxford University Press	Oxford University Press, 2, 0.87% Oxford University Press 2 публикации, 0.87%
Hindawi Limited	Hindawi Limited, 2, 0.87% Hindawi Limited 2 публикации, 0.87%
Cold Spring Harbor Laboratory	Cold Spring Harbor Laboratory, 2, 0.87% Cold Spring Harbor Laboratory 2 публикации, 0.87%
American Society for Pharmacology and Experimental Therapeutics	American Society for Pharmacology and Experimental Therapeutics, 1, 0.43% American Society for Pharmacology and Experimental Therapeutics 1 публикация, 0.43%
Editions E D K	Editions E D K, 1, 0.43% Editions E D K 1 публикация, 0.43%
IOS Press	IOS Press, 1, 0.43% IOS Press 1 публикация, 0.43%
S. Karger AG	S. Karger AG, 1, 0.43% S. Karger AG 1 публикация, 0.43%
Portland Press	Portland Press, 1, 0.43% Portland Press 1 публикация, 0.43%
Pharmaceutical Society of Japan	Pharmaceutical Society of Japan, 1, 0.43% Pharmaceutical Society of Japan 1 публикация, 0.43%
Public Library of Science (PLoS)	Public Library of Science (PLoS), 1, 0.43% Public Library of Science (PLoS) 1 публикация, 0.43%
European Molecular Biology Organization	European Molecular Biology Organization, 1, 0.43% European Molecular Biology Organization 1 публикация, 0.43%
	10 20 30 40 50 60

Мы не учитываем публикации, у которых нет DOI.
Статистика публикаций обновляется еженедельно.

Вы ученый?

Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.

Войти с ORCID

Метрики

231

Цитировать

ГОСТ |

Цитировать

ГОСТ Скопировать

Wilson N. C. et al. An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells // Cancer Cell. 2011. Vol. 19. No. 1. pp. 101-113.

ГОСТ со всеми авторами (до 50) Скопировать

Wilson N. C., Yang B., Yang A., Loeser S., Marsters S., Lawrence D. M., Li Y., Pitti R., TOTPAL K., Yee S., Ross S., Vernes J., Lu Y., Adams C., Offringa R., Kelley B., Hymowitz S. G., Daniel D., Meng G., Ashkenazi A. An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells // Cancer Cell. 2011. Vol. 19. No. 1. pp. 101-113.

RIS |

Цитировать

RIS Скопировать

TY - JOUR

DO - 10.1016/j.ccr.2010.11.012

UR - https://doi.org/10.1016/j.ccr.2010.11.012

TI - An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells

T2 - Cancer Cell

AU - Wilson, Nicholas C.

AU - Yang, Becky

AU - Yang, Annie

AU - Loeser, Stefanie

AU - Marsters, Scot

AU - Lawrence, David M.

AU - Li, Yun

AU - Pitti, Robert

AU - TOTPAL, KLARA

AU - Yee, Sharon

AU - Ross, Sarajane

AU - Vernes, Jean-Michel

AU - Lu, Yanmei

AU - Adams, Cam

AU - Offringa, Rienk

AU - Kelley, Bob

AU - Hymowitz, Sarah G.

AU - Daniel, Dylan

AU - Meng, Gloria

AU - Ashkenazi, Avi

PY - 2011

DA - 2011/01/20

PB - Elsevier

SP - 101-113

IS - 1

VL - 19

PMID - 21251615

SN - 1535-6108

SN - 1878-3686

ER -

BibTex |

Цитировать

BibTex (до 50 авторов) Скопировать

@article{2011_Wilson,

author = {Nicholas C. Wilson and Becky Yang and Annie Yang and Stefanie Loeser and Scot Marsters and David M. Lawrence and Yun Li and Robert Pitti and KLARA TOTPAL and Sharon Yee and Sarajane Ross and Jean-Michel Vernes and Yanmei Lu and Cam Adams and Rienk Offringa and Bob Kelley and Sarah G. Hymowitz and Dylan Daniel and Gloria Meng and Avi Ashkenazi},

title = {An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells},

journal = {Cancer Cell},

year = {2011},

volume = {19},

publisher = {Elsevier},

month = {jan},

url = {https://doi.org/10.1016/j.ccr.2010.11.012},

number = {1},

pages = {101--113},

doi = {10.1016/j.ccr.2010.11.012}

}

MLA

Цитировать

MLA Скопировать

Wilson, Nicholas C., et al. “An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells.” Cancer Cell, vol. 19, no. 1, Jan. 2011, pp. 101-113. https://doi.org/10.1016/j.ccr.2010.11.012.

Издатель

Elsevier

Журнал

Cancer Cell

scimago Q1

wos Q1

БС1

SJR

19.027

CiteScore

57.7

Impact factor

44.5

ISSN

15356108 (Print)

18783686 (Electronic)